Brought to you by 
Fusion Pharmaceuticals brings in $105mm through Series B round
30 May 2019
Executive Summary
Fusion Pharmaceuticals Inc. (radiopharmaceuticals for cancer) raised $105mm through an oversubscribed Series B round led by Varian and OrbiMed. Perceptive Advisors, Pivotal bioVenture Partners, and Rock Springs Capital were joined by returning backers HealthCap, Adams Street Partners, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), TPG Biotech, Seroba Life Sciences, Genesys Capital, and FACIT. OrbiMed, Pivotal bioVenture, and Varian join the company's board. Fusion will use the proceeds to support continued development of its pipeline of alpha therapeutics designed with the company's Fast-Clear platform for linking molecules to medical isotopes.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Fusion Pharmaceuticals brings in $105mm through Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice